MEI Pharma. has filed a patent for combination therapies to treat KRAS mutant cancers. The method involves administering a CDK inhibitor along with an additional therapeutic agent to the patient. Claim 1 specifically mentions the use of a compound of Formula Ib for treatment. GlobalData’s report on MEI Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on MEI Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. MEI Pharma's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Combination therapy for treating kras mutant cancers
A patent application (Publication Number: US20240016781A1) discloses a method for treating KRAS mutant cancer by administering a compound of Formula Ib to a subject in need. The method may also involve the administration of an additional anticancer agent, such as Sotorasib (AMG510) or Adagrasib (MRTX849), among others. The KRAS mutant cancer targeted by this method includes specific mutations like G12A, G12C, G12D, and others. The cancer types that can be treated using this method range from leukemia to lymphoma and various solid tumors like pancreatic, lung, colorectal, and breast cancer.
Furthermore, the patent application details the administration of the compound of Formula Ib in various crystal forms, such as malonate, dibenzoyl-tartrate, phosphate, oxalate, and napadisylate. These crystal forms are characterized by specific X-ray powder diffraction patterns, indicating their unique structures. The dosage and administration schedule of the compound of Formula Ib are also specified, ranging from daily dosing to intermittent schedules like every other day or on a 14 days on/14 days off regimen. The treatment duration can vary from one day to up to 12 months, providing flexibility in the treatment approach for KRAS mutant cancer.
To know more about GlobalData’s detailed insights on MEI Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
